• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 20-F filed by Tiziana Life Sciences Ltd.

    4/30/25 5:00:03 PM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TLSA alert in real time by email
    NT 20-F 1 ea0240274-nt20f_tiziana.htm NOTIFICATION OF LATE FILING

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 12b-25

     

    Commission File Number: 001-38723

     

    NOTIFICATION OF LATE FILING

     

    ☐   Form 10-K ☒   Form 20-F ☐   Form 11-K ☐   Form 10-Q
    ☐   Form 10-D ☐   Form N-SAR ☐   Form N-CSR  

     

    For Period Ended: December 31, 2024

     

    ☐   Transition Report on Form 10-K ☐   Transition Report on Form 10-Q
    ☐   Transition Report on Form 20-F ☐   Transition Report on Form N-SAR
    ☐   Transition Report on Form 11-K  

     

    For the Transition Period Ended: _______________________________________

     

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: _______________________________________

     

    PART I

    REGISTRANT INFORMATION

     

    Full name of registrant Tiziana Life Sciences Ltd
    Former name if applicable  
    Address of principal executive office Clarendon House, 2 Church Street,
    City, state and zip code Hamilton, HM11, Bermuda

     

     

     

     

    PART II

    RULE 12b-25 (b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate.)

     

      (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
    ☒  (b) The subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form N-SAR or Form N-CSR, or portion thereof will be filed on or before the 15th calendar day following the prescribed due date or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III

    NARRATIVE

     

    State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR, N-CSR, or the transition report portion thereof, could not be filed within the prescribed time period.

     

    The compilation, dissemination and review of the information required to be presented in the Form 20-F for the relevant fiscal year has imposed time constraints that have rendered timely filing of the Form 20-F impracticable without undue hardship and expense to the registrant. The registrant undertakes the responsibility to file such annual report no later than 15 days after its original due date.

     

    PART IV

    OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

    Keeren Shah   (44)   (0)20 7495 2379
    (Name)   (Area Code)   (Telephone Number)

      

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

     

    ☒  Yes   ☐   No

     

    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

     

    ☐  Yes   ☒   No

     

    If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    -2-

     

     

    Tiziana Life Sciences, Inc.

    (Name of Registrant as Specified in Charter)

     

    Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

     

    Dated: April 30, 2025   /s/ Keeren Shah
      By: Keeren Shah
      Title: Chief Financial Officer

     

     

    -3-

     

    Get the next $TLSA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TLSA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TLSA
    SEC Filings

    View All

    SEC Form 424B5 filed by Tiziana Life Sciences Ltd.

    424B5 - Tiziana Life Sciences Ltd (0001723069) (Filer)

    1/21/26 6:57:56 PM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form AW filed by Tiziana Life Sciences Ltd.

    AW - Tiziana Life Sciences Ltd (0001723069) (Filer)

    1/21/26 6:55:21 PM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Tiziana Life Sciences Ltd.

    6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)

    1/20/26 11:15:03 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab

    BOSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the peer-reviewed publication of its open-label study in patients with non-active secondary progressive multiple sclerosis (na-SPMS) in Neurology Neuroimmunology & Neuroinflammation, a prestigious journal of the American Academy of Neurology. The publication, titled "Nasal Foralumab for the Treatment of Progression Independent of Relapses in Patients with Non-active Secondary Progressive Multiple Sclerosis," details the comprehensive positive results previously an

    1/20/26 11:15:00 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares

    BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the closing of its previously announced Company best efforts registered direct offering ("Offering") of 7,040,000 ordinary shares at an offering price of $1.25 per ordinary share conducted without an underwriter or placement agent to members of senior management and existing shareholders. The gross proceeds to Tiziana from the Offering, before deducting estimated Offering expenses payable by Tiziana, were $8.8 million. For every ordinary share subscribed, particip

    1/16/26 2:45:30 PM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million

    BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the pricing of a Company best efforts registered direct offering ("Offering") of 6,400,000 ordinary shares at an Offering price of $1.25 per ordinary share conducted without an underwriter or placement agent to members of senior management and existing shareholders. The total gross proceeds to Tiziana from the Offering, before deducting estimated Offering expenses payable by Tiziana, are expected to be $8.0 million. For every ordinary share subscribed, participants

    1/16/26 7:00:00 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zacks Investment Research initiated coverage on Tiziana Life Sciences with a new price target

    Zacks Investment Research initiated coverage of Tiziana Life Sciences with a rating of Not Rated and set a new price target of $7.50

    4/12/21 11:57:17 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLSA
    Leadership Updates

    Live Leadership Updates

    View All

    Tiziana Life Sciences Appoints New Chief Executive Officer

    NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the appointment of Ivor Elrifi as its Chief Executive Officer (CEO), effective immediately. "We are delighted to welcome Ivor Elrifi as the new CEO of Tiziana Life Sciences," said Gabriele Cerrone, Founder and Executive Chairman of the Board. " Ivor has an invaluable track record in creating substantial value for biotech and pharma companies with his strategic vision in building in

    8/19/24 7:00:00 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research

    NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Howard L. Weiner, M.D., Chairman of Tiziana's Scientific Advisory Board and co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital, a founding member of Mass General Brigham healthcare system, is being honored with the prestigious "Giants of MS" award for his outstanding contributions in the area of multiple sclerosis (MS) research. The award ceremony will take place on May 30, 2024 at the Consortium of Multipl

    5/30/24 7:00:00 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer

    Leadership Addition Strengthens Company's Commitment to Advancing Innovative Therapies NEW YORK, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Development Officer. Dr. Clementi will formally take up the CDO role effective September 1, 2023. In this role, Dr. Clementi will be responsible for overseeing the company's development strategies and advancing its portfolio of groundbreaking therapeutic candidates. Dr. Clementi brings with

    8/23/23 10:30:00 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLSA
    Financials

    Live finance-specific insights

    View All

    Tiziana Life Sciences Announces Date of Annual General Meeting 2022

    NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that the 2022 Annual General Meeting of the Company will be held on December 29, 2022. The record date for voting at the Annual General Meeting is set as November 30, 2022. The notice, agenda and associated material have been despatched to shareholders via mail and the notice, agenda and related financial statements in the form of the relevant Form 20-F filing are available on the Company's website at https://ir.tizianalifesciences.com/shareholder-services/annual-ge

    12/6/22 7:00:00 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS)

    NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced a corporate update, including its near-term focus on developing intranasal foralumab for inflammatory diseases of the Central Nervous System (CNS) such as non-active secondary-progressive Multiple Sclerosis (SPMS), Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Gabriele Cerrone, Executive Chairman and interim Chief Executive Officer of Tiziana, remarked, "We look forward to leveraging the exciting clinical and preclinical results from our

    11/10/22 7:00:00 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment

    NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA, LSE: TILS))) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, will host a conference call and audio webcast on Wednesday, September 8, at 4:15 p.m. ET to discuss its recently announced exclusive license agreement to evaluate Foralumab, the Company's novel, fully human anti-CD3 monoclonal antibody, in conjunction with allogenic CAR T candidates for cancer treatment. Date:Wednesday, September 8, 2021  Time:4:15 p.m. Eastern Time  Live Call:+1-877-407-9716 (U.S. Toll-Free) or +1-201-493-6779 (International)

    9/7/21 2:00:00 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tiziana Life Sciences Ltd.

    SC 13G - Tiziana Life Sciences Ltd (0001723069) (Subject)

    5/4/22 4:34:27 PM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Tiziana Life Sciences plc

    SC 13D - Tiziana Life Sciences Ltd (0001723069) (Subject)

    1/4/22 4:31:31 PM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Tiziana Life Sciences plc (0001723069) (Subject)

    2/16/21 7:32:16 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care